Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.

Yuxin Shu,Yan Lu,Xiaojuan Pang,Wei Zheng,Yahong Huang,Jiahong Li,Jianguo Ji,Can Zhang,Pingping Shen
DOI: https://doi.org/10.18632/oncotarget.12764
2016-01-01
Oncotarget
Abstract:Peroxisome proliferator-activating receptor gamma(PPAR gamma), a transcription factor, is involved in many important biological processes, including cell terminal differentiation, survival and apoptosis. However, the role of PPAR gamma, which regulates tumour promoter and oncogene expression, is not well understood in hepatocellular carcinoma (HCC). In the present study, based on evidence from clinical samples that phosphorylation of PPAR gamma at Ser84 is up-regulated in human liver tumours, we confirmed that phosphorylation of PPAR gamma was also significantly increased in an HCC mouse model and was increased by Mitogen-activated protein kinase (MEK)/Extracellular-signal-regulated kinases (ERK) kinase. Next, we performed an RNA microarray analysis, and our data indicated that dephosphorylation of PPAR gamma at Ser84 affects the expression of glycolysis-related genes and pro-proliferation genes, which supposedly promote proliferation of HCC cells. Using a chromatin immunoprecipitation (ChIP) assay, we demonstrated that the observed PPAR gamma-mediated induction of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) expression was directly modulated by the transcriptional activity of its promoter. Furthermore, using knockdown of PFKFB4, we elucidated that the stimulation of PPAR gamma phosphorylation on glycolysis and proliferation in HCC is dependent on PFKFB4. Together, these findings extend our understanding of how liver tumour cells reprogram their glycolytic pathways by post-translational modification of specific transcription factors and lay a foundation for the screening of new targets for the treatment of HCC.
What problem does this paper attempt to address?